Quality of Life
Areas of the most intense research for lupus include genetics, and treatments. Every lupus patient should have their Vitamin D status regularly tested and their levels optimized. (Also see Autoimmune Diseases, Overview of Lupus, Difficult Diagnosis, What is Scleroderma?, and Overlap Syndrome)
Serum level of DNase1l3 in patients with dermatomyositis/polymyositis (DM/PM), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and its association with disease activity. A significant reduction was found in serum DNase1l3 level in DM/PM and SLE, which may associate with clinic features and disease activity. PubMed, Clin Exp Med, 12/30/2016. (Also see Dermatomyositis and Polymyositis and Causes of Rheumatoid Arthritis)
Adipokines, tumor necrosis factor (TNF) and its receptors in female patients with systemic lupus erythematosus (SLE). The correlation between adipokines and TNF system allows a better understanding of the role of adipokines in the inflammatory response in SLE patients. PubMed, Lupus, 06/30/2016.
Effect of menopause hormone therapy on disease progression in systemic lupus erythematosus: A systematic review. Hormone therapy in menopausal patients with systemic lupus erythematosus appears to be well tolerated. PubMed, Maturitas, 2015 Jun;81(2):276-281.
Second-to-fourth Digit Ratio in Systemic Lupus Erythematosus (SLE). The study suggests that patients with SLE have experienced high prenatal testosterone and low prenatal estrogen. PubMed, J Rheumatol, 2015 May;42(5):826-8.
Systemic lupus erythematosus (SLE) is not a risk factor for poor outcomes after total hip and total knee arthroplasty. SLE was not an independent risk factor for poor short-term pain or function after either hip or knee arthroplasty. PubMed, Lupus, 01/16/2015.
Clinical manifestations and survival among adults with systemic lupus erythematosus (SLE) according to age at diagnosis. Ten-year survival rates were lower among late-onset patients. A lupus manifestation as the cause of death was more common among adult-onset compared with late-onset patients. PubMed, Lupus, 2014 Mar 7.
Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome with lupus (APS-SLE). Specific gene signatures explain the pro-atherosclerotic and pro-thrombotic alterations in these highly related autoimmune diseases. PubMed, Ann Rheum Dis, 2014 Mar 11. (Also see Antiphospholid Syndrome)
Re-engineering lupus into a cancer killer. Researchers from the Yale Cancer Center and the Veterans Affairs Greater Los Angeles Healthcare System have devised a way to re-engineer lupus antibodies to turn them into potential cancer killers. Science Daily, 04/21/2015.
Y-27632, a Rho–associated protein kinase inhibitor, inhibits systemic lupus erythematosus. The findings showed that the inhibition of rho-associated, coiled–coil–containing protein kinase 1(ROCK) was beneficial for the prevention of systemic lupus erythematosus, which possibly by suppressing NF-?B activation. PubMed, Biomed Pharmacother, 2017 Apr;88:359-366. (Also see Interleukins)
Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus (SLE) and Sjögren's syndrome (pSS). Functional LILRA3 is a new susceptibility factor for SLE and pSS and it highly predisposes to certain phenotypes such as leucopenia, thrombocytopenia and autoantibody-positive subphenotypes. PubMed, Ann Rheum Dis, 2015 Nov;74(11):2070-5. (Also see Sjögren's Syndrome Research)
The role of neutrophils in the pathogenesis of systemic lupus erythematosus. Neutrophils, low–density granulocytes and aberrant neutrophil extracellular trap formation and clearance play important roles in lupus pathogenesis. PubMed, Current Opinion in Rheumatology, 08/03/2015.
Active disease is independently associated with more severe anxiety rather than depressive symptoms in patients with systemic lupus erythematosus (SLE). Anxiety is more common in lupus patients than in healthy controls and its severity is independently associated with more active SLE regardless of the presence or absence of concomitant depression. PubMed, Lupus, 06/17/2015. (Also see Anxiety and Attitude)
Serum 25–OH vitamin D level in treatment–naïve systemic lupus erythematosus (SLE) patients: Relation to disease activity, IL-23 and IL-17. Hypovitaminosis D contributes to ANA antibody production and is associated with high serum levels of IL-23 and IL-17 and may trigger the inflammatory process in SLE. Lupus, 12/07/2016. (Also see Interleukins)
Low levels of calcium or vitamin D, which is more important in systemic lupus erythematosus patients? An extensive data analysis. Calcium levels may play a significant role in the SLE disease process, more than originally thought, since SLE patients are at a higher risk for hypocalcaemic events. Clinical and Experimental Rheumatology Online, 09/01/2016. (Also see Vitamin D Deficiency)
Vitamin D and systemic lupus erythematosus (SLE): continued evolution. This reviews the recent literature regarding vitamin D and SLE, as well as current recommendations for vitamin D supplementation in patients with SLE. PubMed, Int J Rheum Dis, 2014 Dec 19.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: